Sygenus shows longer lasting effect on pain than morphine

Tuesday, 26 September 2017

Sygenus technology shows more potent and longer lasting effect on pain than morphine.

Regeneus (ASX: RGS), a clinical-stage regenerative medicine company, today announced that a preclinical post-operative pain study has shown that topical application of Sygenus, has significantly greater and longer lasting analgesic effect than an injection of morphine.

Sygenus is an allogeneic cell secretions technology platform that comprises cytokines, growth factors and exosomes from adipose-derived mesenchymal stem cells (MSCs). These bioactive molecules are known to reduce pain and inflammation and encourage accelerated healing and repair.

These promising results show that Sygenus is having a sustained analgesic effect above and beyond the anti-inflammatory effect that others have observed with MSCs and their secretions.